SOVALDI Drug Patent Profile

When do Sovaldi patents expire, and what generic alternatives are available?

Sovaldi is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty-eight patent family members in forty-nine countries.

The generic ingredient in SOVALDI is sofosbuvir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Sovaldi

Sovaldi was eligible for patent challenges on December 6, 2017.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SOVALDI

International Patents:	368
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	49
Clinical Trials:	34
Drug Prices:	Drug price information for SOVALDI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOVALDI
What excipients (inactive ingredients) are in SOVALDI?	SOVALDI excipients list
DailyMed Link:	SOVALDI at DailyMed

See drug prices for SOVALDI

Recent Clinical Trials for SOVALDI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ain Shams University	Phase 3
Cairo University	Phase 3
Assiut University	Early Phase 1

See all SOVALDI clinical trials

Pharmacology for SOVALDI

Drug Class	Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	RNA Replicase Inhibitors

Paragraph IV (Patent) Challenges for SOVALDI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOVALDI	Tablets	sofosbuvir	400 mg	204671	2	2017-12-06

US Patents and Regulatory Information for SOVALDI

SOVALDI is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-002	Aug 28, 2019		RX	Yes	Yes
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-002	Aug 28, 2019		RX	Yes	No					Y

EU/EMA Drug Approvals for SOVALDI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Sovaldi	sofosbuvir	EMEA/H/C/002798Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.	Authorised	no	no	no	2014-01-16

International Patents for SOVALDI

When does loss-of-exclusivity occur for SOVALDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SOVALDI around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I498117
World Intellectual Property Organization (WIPO)	2013082003
China	102906102
Morocco	36906	Procédés permettant de traiter le virus de l'hépatite c (hcv)
Luxembourg	92600
Spain	2638350
Malaysia	187735

Supplementary Protection Certificates for SOVALDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	C20140035	Estonia		PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
2635588	C02635588/01	Switzerland		PRODUCT NAME: VELPATASVIR + SOFOSBUVIR + VOXILAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66510 08.12.2017
2203462	92600	Luxembourg		PRODUCT NAME: SOVALDI (SOFOSBUVIR); AUTHORISATION NUMBER AND DATE: EU/1/13/894(001-002) - SOVALDI - SOFOSBUVIR 20140117
2203462	214 5029-2014	Slovakia		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462	PA2014040,C2203462	Lithuania		PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2203462	2014/065	Ireland		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-EU/1/13/894/002 20140116
2203462	67/2014	Austria		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117

Market Dynamics and Financial Trajectory of Sovaldi

Last updated: February 20, 2026

What is Sovaldi?

Sovaldi (sofosbuvir) is an antiviral drug developed by Gilead Sciences, approved in 2013 for the treatment of hepatitis C virus (HCV) infection. It is the first in a class of direct-acting antivirals (DAAs), revolutionizing HCV therapy with high cure rates and simplified regimens.

Market Size and Growth Drivers

Year	Estimated Global HCV Population	Market Size (USD billions)	Key Drivers
2013	130 million	3.2	Rise in HCV diagnosis, initial pricing strategies
2018	71 million	15.6	Greater diagnosis rates, expanded indications
2022	58 million	19.8	Increased access, generic competition in some markets

Drivers:

• Rising Diagnosis and Awareness: WHO estimates 58 million people infected globally (WHO, 2022).
• Improved Treatment Outcomes: High cure rates (>95%) with short-duration therapy.
• Pricing and Reimbursement Policies: Initially high prices, with subsequent price reductions and negotiations.
• Generic Entry: Limited in high-income markets but present in low- and middle-income countries.
• Regulatory Approvals: Broader indication approvals expand market access.

Market Dynamics

Competitive Landscape

Product	Year Approved	Price (USD per treatment)	Market share (2022)	Key Features
Sovaldi (sofosbuvir)	2013	84,000 (U.S.)	60%	High efficacy, simplified regimens, patent exclusivity
Harvoni (ledipasvir + sofosbuvir)	2014	94,500	25%	Once-daily, pangenotypic, combination therapy
Epclusa (sofosbuvir + velpatasvir)	2016	75,000	10%	Pangenotypic, high efficacy across genotypes
Generic versions	2018–present	1,000–10,000 (varies)	5–15% in some markets	Government and NGO programs leverage generics

Market consolidation and price competition have driven down costs, especially in developing countries.

Pricing Trends and Reimbursement

• US list price initially at $84,000 for 12 weeks.
• By 2022, negotiated prices in public programs in Europe and Asia range between $20,000 and $30,000 per treatment course.
• Discounting and generics have substantially lowered prices in emerging markets.

Patent Expiry and Generic Competition

• Patent protections in major markets extended until 2028–2030.
• Multiple generic manufacturers approved in India, Egypt, and other countries.
• Reduced pricing and increased access in low-income countries bolster market expansion.

Financial Performance and Trajectory

Year	Revenue (USD billions)	Operating Margin	R&D Investment (USD millions)	Comments
2013	3.35	70%	2,000	Launch year, high initial sales
2018	12.4	55%	3,500	Peak sales, expanded indications
2022	9.0	50%	2,000	Mature phase, market saturation, decline in some regions
2023*	7.8 (projected)	52%	1,800	Slight decline, shift towards broader antiviral portfolio

*Estimate based on company reports and analyst forecasts.

Revenue Drivers

• Global treatment initiatives in low-income countries.
• Expanded indications in pediatric and contraindicated populations.
• Declining treatment costs that support broader access.

Revenue Risks

• Patent expirations reducing exclusivity.
• Increased generic competition.
• Market saturation in high-income countries.
• Emergence of new antiviral agents.

Future Outlook

• Market Penetration: Continued expansion in Africa, Southeast Asia, and Latin America.
• Pricing Trends: Further price reductions aligned with generic competition.
• New Formulations: Development of longer-acting or combination therapies may displace Sovaldi.
• Regulatory Changes: Policy shifts towards universal coverage could enhance access and volume.

Estimated global HCV treatment market is expected to decline modestly post-2030 as global prevalence decreases and therapies become more affordable.

Key Takeaways

• Sovaldi launched as a breakthrough hepatitis C treatment with high efficacy.
• Peak revenues reached approximately USD 12.4 billion in 2018.
• Patent protections and brand exclusivity cast a gradual decline from 2028 onward.
• Generics have significantly impacted pricing and access, especially in emerging markets.
• Continued expansion hinges on public health initiatives and evolving treatment landscapes.

FAQs

1. How does generic competition impact Sovaldi’s market share?
Generics reduce prices, particularly in low-income countries, limiting brand revenue and market dominance in those regions.

2. What are the primary factors influencing Sovaldi’s pricing strategies?
Pricing depends on market income levels, negotiating power of payers, patent status, and availability of generics.

3. How does patent expiration influence future revenue?
Patent expiration permits generic manufacturers to produce lower-cost versions, leading to significant revenue decline in affected markets.

4. What markets are driving future growth for hepatitis C therapies?
Low- and middle-income countries, where access programs and generic manufacturing expand treatment.

5. Will Sovaldi remain relevant after patent expiry?
Yes, as part of combination regimens and in regions with limited generics, but overall revenue will decline with increased competition.

---

References

1. World Health Organization. (2022). Hepatitis C. WHO.
2. Gilead Sciences. (2023). Annual Report 2022.
3. MarketWatch. (2022). Hepatitis C Virus Therapeutics Market Size, Trends & Forecasts.
4. U.S. Food and Drug Administration. (2013). Sovaldi Approval Announcement.
5. IMS Health. (2018). Global Hepatitis C Market Data.